TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33306114
Drug: Social norm
Normalized name: K Norm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social norm email feedback program (2 emails with evidence-based information about nimodipine and individual prescription levels)
Study: 33306114
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (opened emails)
Study: 35863486
Drug: Tobramycin Inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin Inhalation Solution (300 mg/5 ml twice daily)
Study: 35863486
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline 5 ml twice daily)
Study: 33347814
Drug: PARP inhibitors
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP inhibitors
Study: 32134291
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy adapted for patients with IBS (MBCT-IBS)
Study: 33030515
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2, days 1, 8, and 15 every 4 weeks)
Study: 33030515
Drug: Paclitaxel with
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel with Bevacizumab (10 mg/kg, every 2 weeks for 6 cycles, followed by maintenance bevacizumab 15 mg/kg every 3 weeks)
Study: 35894080
Drug: Liraglutide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (3 mg subcutaneously daily)
Study: 33247483
Drug: Citalopram (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (up to 40 mg/day) plus Tipepidine (30 mg twice daily)
Study: 33247483
Drug: Citalopram (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (up to 40 mg/day) plus Placebo
Study: 32272022
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) - budesonide
Study: 33752439
Drug: Early rule-out
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rule-out pathway using high-sensitivity cardiac troponin I concentrations <5 ng/L at presentation.
Study: 32960309
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment of Lisfranc injuries
Study: 32815804
Drug: ISBPB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISBPB with 20 cc of 0.25% levobupivacaine + 3.3 mg dexamethasone (group LD)
Study: 32815804
Drug: ISBPB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISBPB with 20 cc of 0.25% levobupivacaine (group L)
Study: 32683388
Drug: Polytetrafluoroethylene (PTFE)
Normalized name: polytetrafluoroethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polytetrafluoroethylene (PTFE) strips as an adjunct to epinephrine impregnated gauze
Study: 34036728
Drug: Multimicronutrient‐fortified lipid‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimicronutrient‐fortified lipid‐based nutrient supplement containing 250‐μg I per day started immediately after randomization (Arm 1)
Study: 34036728
Drug: Multimicronutrient‐fortified lipid‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimicronutrient‐fortified lipid‐based nutrient supplement containing 250‐μg I per day started at 12 weeks gestation (Arm 2)
Study: 34036728
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention supplement (Arm 3)
Study: 35849009
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (3.5 g) of EPA + DHA
Study: 35849009
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (2.0 g) of EPA + DHA
Study: 34254892
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behaviour therapy for perfectionism (ICBT-P)
Study: 34254892
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (access to treatment 8 weeks post-randomisation)
Study: 35266378
Drug: Ultrasound-guided serratus
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided serratus plane block (SPB) with 30 mL 0.25% bupivacaine
Study: 35266378
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 2 mL saline injection subcutaneously
Study: 34932077
Drug: Proactive therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive therapeutic drug monitoring (TDM) with dose and interval adjustments based on scheduled monitoring of serum drug levels and antidrug antibodies (n=228)
Study: 34932077
Drug: Standard infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard infliximab therapy without drug and antibody level monitoring (n=230)
Study: 35121062
Drug: Yerba mate
Normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yerba mate infusion (300 mL)
Study: 35121062
Drug: Hot tea
Normalized name: ChoreMate One-Shot Teat Dip 1 % (titratable iodine concentrate 3.6 % ) Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot tea (300 mL)
Study: 35121062
Drug: Cold tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold tea (300 mL)
Study: 35121062
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of hot tea and yerba mate infusion
Study: 32408846
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) for 8 weeks
Study: 36502333
Drug: M. officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. officinalis extract (500 mg of RA per day)
Study: 34478124
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection (RCI; Acthar® Gel) 80 U subcutaneously every other day for 4 weeks and then twice weekly through week 24
Study: 34478124
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection (RCI; Acthar® Gel)
Study: 36369781
Drug: Ultrasound-guided genicular
Normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided genicular nerve block (GNB) with 5.7 mg celestone chronodose (1 ml) and 0.5% bupivacaine (3 ml)
Study: 33952684
Drug: Obturator nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obturator nerve block with 20 mL of ropivacaine 0.2%
Study: 32701129
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus radiotherapy (IMRT after chemotherapy)
Study: 34724405
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) intervention teaching pain self‐management skills in 12 weekly, 90‐minute groups delivered by an interdisciplinary team.
Study: 34553395
Drug: GSH-FBT (online
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSH-FBT (online guided self-help family-based treatment) for parents, 12 sessions of 20 minutes each
Study: 34553395
Drug: FBT-V (family-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBT-V (family-based treatment delivered via videoconferencing), 15 sessions of 60 minutes each
Study: 33067703
Drug: Carboplatin (AUC5)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (AUC5) and bevacizumab (10 mg/kg) every 3 weeks
Study: 35610297
Drug: Commercial activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial activity tracker bracelet with daily activity goal and inactivity alerts for 12 months
Study: 616774613
Drug: Endoscopic concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic concurrent therapy
Study: 616774613
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (Control)
Study: 32463470
Drug: Bupropion (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (150 mg for 4 weeks plus 300 mg for 8 weeks)
Study: 36280809
Drug: ECD program
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECD program with monthly developmental feedback
Study: 33169672
Drug: Tezepelumab (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab (70 mg every 4 weeks, 210 mg every 4 weeks, or 280 mg every 2 weeks)
Study: 32103903
Drug: Cefotetan disodium
Normalized name: Cefotetan Disodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan disodium 1.0 g BID for 7 days
Study: 32915004
Drug: Control (listing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (listing daily activities and reflecting on obstacles and benefits)
Study: 35381421
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion at 25 µg/min
Study: 34152206
Drug: Conidial suspension
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conidial suspension (106 conidia mL‐1) of Fusarium oxysporum isolates, applied by pouring 50 ml per pot.
Study: 34152206
Drug: Sterile distilled
Normalized name: petroleum distillate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile distilled water (control) applied by pouring 50 ml per pot.
Study: 33993273
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (β‐lactam plus aminoglycoside or quinolone)
Study: 33993273
Drug: Monotherapy (β‐lactam)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (β‐lactam)
Study: 32667636
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (clinician's choice, CC)
Study: 32923335
Drug: Tablet-based worked
Normalized name: Apis cerana worker secretion preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based worked examples (G2)
Study: 35765103
Drug: UC-MSCs (1 × [Formula:
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSCs (1 × [Formula: see text] cells/kg BW per injection) every other day for three injections
Study: 33176886
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate at 4 mmol/L associated with unfractionated heparin at 10 U/Kg/h (Group B)
Study: 33176886
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate at 4 mmol/L (Group A - control)
Study: 35485381
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg subcutaneously plus standard of care (group A)
Study: 35485381
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg subcutaneously (group A)
Study: 33538248
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg/day
Study: 32219884
Drug: Double-blind, placebo-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind, placebo-controlled oral food challenges (DBPCFC)
Study: 33424840
Drug: PEG‐IFNα‐2b therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFNα‐2b therapy
Study: 33424840
Drug: Anti‐CD24 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐CD24 antibody treatment
Study: 32073648
Drug: Tivantinib (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib (360 mg twice daily) plus Cetuximab (500 mg/m2 every 2 weeks)
Study: 32073648
Drug: Cetuximab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (500 mg/m2 every 2 weeks)
Study: 32073648
Drug: Tivantinib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib monotherapy
Study: 35017288
Drug: Traditional Treatment
Normalized name: Midol Traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Treatment (TM)
Study: 36122589
Drug: Individualized homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized homeopathic medicines (IHMs) in fifty‐millesimal (LM) potencies
Study: 34316017
Drug: Midostaurin in
Normalized name: Product containing midostaurin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin in addition to intensive chemotherapy
Study: 32826637
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) therapy for 3 min
Study: 35149574
Drug: Provision of
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provision of progestogen only pill (POP) with emergency contraception (EC) from pharmacies as routine practice
Study: 36206498
Drug: Toripalimab 240
Normalized name: toripalimab 240 mg in 6 mL INTRAVENOUS INJECTION [LOQTORZI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab 240 mg plus chemotherapy
Study: 36206498
Drug: Toripalimab 240
Normalized name: toripalimab 240 mg in 6 mL INTRAVENOUS INJECTION [LOQTORZI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab 240 mg plus chemotherapy with high tumor mutational burden
Study: 36206498
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy with high tumor mutational burden
Study: 36206498
Drug: Toripalimab 240
Normalized name: toripalimab 240 mg in 6 mL INTRAVENOUS INJECTION [LOQTORZI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab 240 mg plus chemotherapy with mutations in the focal adhesion-PI3K-Akt signaling pathway
Study: 36075242
Drug: Pirfenidone (2403
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone (2403 mg daily)
Study: 36296958
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + high-protein diet (1.2-1.5 g/kg)
Study: 36296958
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + high-protein and omega-3-enriched diet (2.2 g/day)
Study: 33462825
Drug: Acarbose tablet
Normalized name: Acarbose Tablets
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose tablet (50 mg and 100 mg) administered by chewing
Study: 33462825
Drug: Acarbose tablet
Normalized name: Acarbose Tablets
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose tablet (50 mg and 100 mg) administered by swallowing
Study: 34648425
Drug: Self-monitoring followed
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-monitoring followed by CBT-I concurrent with PAP
Study: 32019736
Drug: PRBCs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRBCs with Hb content ≥50 g (Group I, n = 80)
Study: 35598427
Drug: Against Stigma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Against Stigma Program (60-minute weekly sessions for 6 weeks)
Study: 35598427
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (Control group)
Study: 34747087
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (Hb transfusion threshold <75 g/L)
Study: 34747087
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (Hb <95 g/L for operating room or ICU; <85 g/L for ward)
Study: 33148667
Drug: PIPAC oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PIPAC oxaliplatin at 45 mg/m2
Study: 33148667
Drug: PIPAC oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PIPAC oxaliplatin at 90 mg/m2
Study: 33148667
Drug: PIPAC oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PIPAC oxaliplatin at 120 mg/m2
Study: 33148667
Drug: PIPAC oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PIPAC oxaliplatin (all doses)
Study: 36102593
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Therapy (VRT)
Study: 33165566
Drug: Inactivated Influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated Influenza Vaccine (IIV3)
Study: 33165566
Drug: Inactivated Poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated Poliovirus Vaccine (IPV)
Study: 33138797
Drug: Additive models
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additive models in edgeR for pre- and post-treatment groups
Study: 32035552
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg bimekizumab
Study: 32035552
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg bimekizumab
Study: 32035552
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg bimekizumab with a one-off 320 mg loading dose
Study: 32035552
Drug: Bimekizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab (all doses combined)
Study: 34103066
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (30 mg/kg/day)
Study: 35607975
Drug: Daily written
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily written updates on the satisfaction and psychologic symptoms of families of ICU patients
Study: 33821928
Drug: Minimal Contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal Contact Cognitive Behavioral Therapy (MC-CBT)
Study: 33821928
Drug: Standard Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Cognitive Behavioral Therapy (S-CBT)
Study: 33357641
Drug: sacubitril/valsartan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan 200 mg twice-daily
Study: 33357641
Drug: enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 10 mg twice-daily
Study: 34473295
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 4000 IU daily for 24 months
Study: 34264296
Drug: Combined Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined Atropine and Patching Therapy (CAPT)
Study: 34286560
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg plus nutritional supplement (Panax ginseng, Moringa Oleifera, Rutin) once daily for 3 months
Study: 34286560
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg plus placebo once daily for 3 months
Study: 32668113
Drug: Roflumilast 0.3%
Normalized name: ROFLUMILAST 0.3% FOAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 0.3% cream
Study: 32668113
Drug: Roflumilast 0.15%
Normalized name: ROFLUMILAST 0.15% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 0.15% cream
Study: 32668113
Drug: Roflumilast 0.3%
Normalized name: ROFLUMILAST 0.3% FOAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 0.3% cream (for patients with baseline intertriginous psoriasis of at least mild severity)
Study: 32668113
Drug: Roflumilast 0.15%
Normalized name: ROFLUMILAST 0.15% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 0.15% cream (for patients with baseline intertriginous psoriasis of at least mild severity)
Study: 32668113
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream (for patients with baseline intertriginous psoriasis of at least mild severity)
Study: 35286526
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment over left dorsolateral prefrontal cortex (DLPFC) for 20 min
Study: 36271950
Drug: 200-mg ibuprofen
Normalized name: ibuprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg ibuprofen
Study: 36271950
Drug: 600-mg ibuprofen
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600-mg ibuprofen
Study: 36071224
Drug: Genomic analyses
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genomic analyses to target therapy
Study: 38566240
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (exact dosage and duration not specified)
Study: 33215762
Drug: Nilotinib 150
Normalized name: nilotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib 150 mg
Study: 33215762
Drug: Late-start nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late-start nilotinib 150 mg
Study: 33215762
Drug: Nilotinib 150
Normalized name: nilotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib 150 mg vs 300 mg
Study: 35106880
Drug: 26 μg
Normalized name: gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 26 μg LSD
Study: 35106880
Drug: 13 μg
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13 μg LSD
Study: 32986363
Drug: Cervical cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical cancer treatment modalities (radiotherapy, brachytherapy, chemotherapy, surgery)
Study: 32036491
Drug: Mirtazapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15 mg daily on days 2-4)